MannKind Corporation develops patient-focused drug therapies and innovative technology solutions.
We specialize in innovative technologies with proven ease-of-use and patient acceptance.
Needle-free, self-administered Inhalation Treatment Systems for both chronic and acute diseases.
Our Technosphere® technology can accommodate a wide variety of APIs required by specific drug therapies.
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. More
New Afrezza Website is Live
Afrezza®, the only inhaled rapid-acting mealtime insulin in the U.S. commercialized by MannKind, has launched a new website. The site includes a fresh design for easier access to the answers you need, a new blog feature, and an expanded FAQ list. For more information, visit www.afrezza.com
|May 09, 2018||MannKind Corporation Reports 2018 First Quarter Financial Results… More|
|May 09, 2018||MannKind and Cipla Enter an Exclusive Marketing and Distribution Agreement for Afrezza® in India… More|
|May 02, 2018||MannKind Corporation to Hold 2018 First Quarter Financial Results Conference Call on May 9, 2018… More|
|Apr 25, 2018||FDA Determines that Afrezza REMS Communication Plan Has Met Goals and REMS No Longer Necessary… More|
If you are reporting an Adverse Event and/or device complaint, please contact MannKind Medical Information at 1-877-323-8505 or MannKind@druginfo.com. Do not use this form for adverse events and/or device complaints.